-
CUDC-907: Dual PI3K/HDAC Workflow Guide
2026-09-15
CUDC-907 (SKU A4097) is a dual PI3K and HDAC inhibitor for coordinated interrogation of PI3K/AKT signaling, histone acetylation, cell-cycle progression, and apoptosis in cancer research models. This dossier-based guidance supports controlled in vitro workflows only; the compound is not intended for diagnostic, therapeutic, or clinical use.
-
KCNE4-Dependent Modulation of Kv1.3 Pharmacology
2026-09-15
The reference study shows that the leukocyte auxiliary subunit KCNE4 changes Kv1.3 blocker behavior without measurably changing blocker affinity. Its stoichiometry-dependent slowing of intracellular Psora-4 inhibition highlights why channel composition and kinetic readouts matter when interpreting Kv1.3 pharmacology in immune-cell research.
-
How Kinase Inhibitors Accelerate p38α Dephosphorylation
2026-09-14
The reference preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also expose the activation-loop phosphothreonine to WIP1, accelerating dephosphorylation. Structural and biochemical results establish a dual-action mechanism that could guide more selective kinase-inhibitor design, while remaining preliminary for cellular and therapeutic translation.
-
iRhom2 in Olfaction and Odor-Driven Adaptation
2026-09-14
Azzopardi and colleagues identify iRhom2 as a distinctive regulator in olfactory sensory neurons and connect its expression with odor-dependent changes in olfactory receptor and activity-gene programs. The study combines mouse genetics, transcriptomics, in situ hybridization, and an ectopic receptor model to propose an iRhom2/ADAM17-linked feedback mechanism, while also defining important limits on causal interpretation.
-
Monomethyl auristatin E: A State-Aware ADC Assay
2026-09-13
Monomethyl auristatin E (MMAE) is a powerful antibody-drug conjugate payload, but potency alone does not explain response. This article connects MMAE assay design with EBV-driven cancer cell plasticity research to show how phenotype, payload delivery, and mitotic vulnerability can be measured together.
-
EGF-Driven Migration Without EMT in A549 Cells
2026-09-12
The reference study shows that EGF can stimulate A549 lung adenocarcinoma cell migration without substantially inducing epithelial–mesenchymal transition or invasion. Its comparison with TGF-β separates motility from invasive behavior and highlights MAPK-dependent, stimulus-specific mechanisms that should inform migration and metastasis assay design.
-
CHI3L1-IN-5: Astrocyte Assay Workflows
2026-09-12
CHI3L1-IN-5, also called Compound Z17, supports a dual readout strategy: suppressing CHI3L1-driven inflammation while testing astrocyte Aβ clearance and lysosomal recovery. This workflow-focused guide covers dose design, CNS-relevant interpretation, assay controls, and troubleshooting for Alzheimer’s disease and neuroinflammation research.
-
Merbromin Inhibits SARS-CoV-2 3CLpro
2026-09-11
A high-throughput enzyme screen of approximately 6,000 compounds identified Merbromin as a selective, mixed-type inhibitor of the SARS-CoV-2 3CLpro/Mpro protease. The study combines kinetic analysis, binding measurements, and molecular docking to show how this fluorescent antibacterial compound can serve as a starting point for antiviral screening and protease-inhibitor design.
-
Flumequine as a DNA Topoisomerase II Inhibitor
2026-09-11
Flumequine is a synthetic chemotherapeutic antibiotic described as a DNA topoisomerase II inhibitor with a supplier-reported IC50 of approximately 15 μM. Its defined solubility, storage, purity, and viability-assay considerations support controlled DNA replication research while limiting interpretation to the reported assay context.
-
MLN4924 HCl Salt in NAE Research
2026-09-10
MLN4924 HCl salt enables controlled interrogation of NAE-dependent protein turnover, cullin-RING ligase activity, and cell-death signaling. Its strongest use-case is a staged workflow that connects biochemical pathway inhibition with cancer biology research and virus-induced inflammation assays.
-
RNA Pol II Degradation and Regulated Cell Death
2026-09-10
Harper et al. show that RNA Pol II inhibition can trigger apoptosis through active sensing of RNA Pol IIA depletion rather than through transcriptional collapse alone. Their PDAR model separates polymerase abundance from transcriptional activity and provides a framework for interpreting drug-induced cell death in mechanistic cancer biology research.
-
Cefotaxime: A Transferability Lens for AMR Assays
2026-09-09
Cefotaxime is a third-generation cephalosporin antibiotic that can do more than establish susceptibility endpoints. This article shows how to use it as a controlled phenotypic probe alongside plasmid, mobility, and strain-typing data in antimicrobial resistance research.
-
PP2A, Autophagy, and Candida Biofilm Resistance
2026-09-09
The reference study identifies a PP2A–Atg13–Atg1 regulatory axis that connects autophagy with Candida albicans biofilm formation and antifungal drug resistance. By combining PPH21 deletion, rapamycin-induced autophagy, cellular assays, and an oral infection model, it suggests that disrupting PP2A-dependent autophagy may improve antifungal treatment responses.
-
Ceftolozane Sulfate: From Target to Translation
2026-09-08
Ceftolozane sulfate connects PBP3-directed bactericidal activity with reproducible susceptibility and PK/PD research. This guide presents an assay-to-model framework that clarifies ceftolozane MIC values, experimental controls, and translational limitations.
-
SB-505124 hydrochloride for TGF-β Assays
2026-09-08
Use SB-505124 hydrochloride to separate TGF-β/activin-driven Smad signaling from downstream fibrosis, differentiation, and cell-mechanics phenotypes. This workflow also shows how to extend pathway inhibition into mechanobiology assays without confusing ALK signaling effects with direct potassium-channel modulation.